SCHEMBL6171595

SCHEMBL6171595

CCOc1cccc(-c2cc(=O)[nH]c3ccc(Br)cc23)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.49
KDM4E B2RXH2 3/20 0.49
GAA P10253 1/20 0.49
THRB P10828 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
MEN1 O00255 6/20 0.43
KMT2A Q03164 6/20 0.43
HSD17B10 Q99714 2/20 0.43
ALDH1A1 P00352 2/20 0.43
TSHR P16473 1/20 0.43
CLK1 P49759 1/20 0.42
CDK5 Q00535 1/20 0.42
CDK5R1 Q15078 1/20 0.42
SMN1; SMN2 Q16637 4/20 0.42
TP53 P04637 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
ICMT O60725 1/20 0.42
ESR2 Q92731 1/20 0.42
HPGD P15428 2/20 0.40
MAPK1 P28482 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31253416 0.86 SMN1; SMN2 (0.56) MAPTKDM4EGAATDP1MEN1
SCHEMBL26566752 0.86 SMN1; SMN2 (0.56) MAPTKDM4EGAATDP1MEN1
SCHEMBL12277483 0.77 RXFP1 (0.67) MAPTKDM4EGAAMEN1KMT2A
SCHEMBL1757943 0.77 MEN1 (0.62) MEN1KMT2AALDH1A1SMN1; SMN2RXFP1
SCHEMBL25652542 0.75 MAPT (0.49) MAPTKDM4EGAAMEN1KMT2A
SCHEMBL6171731 0.74 FNTA (0.47) MAPTKDM4EGAATHRBTDP1
SCHEMBL3016613 0.74 AR (0.53) MAPTKDM4EGAATHRBTDP1
SCHEMBL25652535 0.73 RXFP1 (0.45) MAPTKDM4EGAAMEN1KMT2A
SCHEMBL6170480 0.71 LTB4R (0.45) MAPTKDM4EMEN1KMT2AHSD17B10
SCHEMBL6587824 0.71 CYP3A4 (0.50) MAPTKDM4EGAATHRBTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1150973-B1 HETEROARYL-SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER PROD INC (US) 2005-06-15 EP disclosed
US-6710209-B2 INHIBITING FARNESYL PROTEIN TRANSFERASE. PFIZER INC 2004-03-23 US disclosed
US-20020120145-A1 Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents PFIZER INC. 2002-08-29 US disclosed
US-6388092-B2 ANTITUMOR AGENT PFIZER INC 2002-05-14 US disclosed
US-20020019530-A1 Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents YANG BINGWEI V (US) 2002-02-14 US disclosed
EP-1150973-A1 HETEROARYL-SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS Pfizer Products Inc. (US) 2001-11-07 EP disclosed
US-6258824-B1 TREATMENT OF HYPERPROLIFERATIVE DISEASES, SUCH AS CANCERS, IN MAMMALS. THIS INVENTION ALSO RELATES TO A PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS. PFIZER INC. 2001-07-10 US disclosed
WO-2000047574-A1 HETEROARYL-SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER PRODUCTS INC. (US) 2000-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120145-A1 Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents NRAS, CCNA1, KRAS MAPT 4805/4885KDM4E 2230/4885GAA 1236/4885
US-20020019530-A1 Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents NRAS, CCNA1, KRAS MAPT 4805/4885KDM4E 2230/4885GAA 1236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.